NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Category: FDA

3 6/22/2016

What’s at stake in the FDA’s decision on eteplirsen, an experimental muscular dystrophy drug

6/13/2016

21st Century Cures Act nears passage with little news media scrutiny

3 5/23/2016

Inside the Sausage Factory of Drug Approval: Nuplazid (pimavanserin) coverage didn’t inspect closely enough

8 4/20/2016

Media mystery: Why did journalists ignore an important study on a costly, harmful back pain procedure?

4 3/16/2016

Coverage of Amarin off-label promotion agreement should have acknowledged deadly history of such marketing

1 2/29/2016

Precision Medicine at one year: A soaring White House summit and the potholes ahead

7 2/10/2016

Groups push pharma agenda under the guise of patient advocacy

1/15/2016

Faulty medical devices stay on the market even after manufacturers know there are problems

3 1/7/2016

“Thousands of lives lost”? Why calls for faster drug approvals need more scrutiny

5 1/5/2016

FDA teams up with medical device industry to write 21st Century Cures Act